HELIOS-A: A Study of Vutrisiran (ALN-TTRSC02) in Patients With Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)

NCT03759379 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

164

Enrollment

INDUSTRY

Sponsor class

Conditions

Amyloidosis, Hereditary
Transthyretin Amyloidosis

Interventions

DRUG: Patisiran
DRUG: Vutrisiran

Sponsor

Alnylam Pharmaceuticals